ArticleUpdates in surgery2026
Calcium-stimulated calcitonin and procalcitonin in borderline hypercalcitoninemia: histopathologic and nodal correlates in a thyroidectomy cohort.
Article in Updates in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mild basal calcitonin elevation represents a diagnostic gray zone in patients undergoing thyroid surgery for non-medullary thyroid carcinoma (MTC) indications. We evaluated calcium-stimulated calcitonin and procalcitonin kinetics according to final histopathology and nodal status in this setting. This retrospective study included 37 adults with reproducible borderline basal calcitonin elevation (< 50 pg/mL) selected from 577 patients who underwent total thyroidectomy for non-MTC indications between 2021 and 2024. All patients underwent calcium stimulation testing with measurement of calcitonin and procalcitonin at baseline and after stimulation. Biochemical responses were compared with final histopathology. Median basal calcitonin was 13.1 [11.0-16.8] pg/mL and median peak stimulated calcitonin (psCT) was 480 [320-790] pg/mL. Final histopathology showed MTC in seven patients (18.9%), all microcarcinomas, C-cell hyperplasia (CCH) without MTC in nine, and no C-cell pathology in 21. Median psCT was highest in MTC, intermediate in CCH without MTC, and lower in patients without C-cell pathology (820 [640-1040], 460 [310-670], and 360 [270-540] pg/mL, respectively; nominal p = 0.047 for MTC vs CCH). psCT values ≥ 500 pg/mL were observed in 6 of 7 MTC cases compared with 1 of 9 CCH cases without MTC. Central lymph-node metastasis was documented in 3 of 7 MTC patients and was accompanied by numerically higher psCT and fold-rise values. wf45g6 Procalcitonin increment and fold-rise were greater in MTC than in CCH without MTC, but no stable procalcitonin-based threshold or combined rule was identified. Occult micro-MTC may show marked calcium-stimulated calcitonin responses despite mild basal hypercalcitoninemia. These findings are exploratory and do not validate diagnostic or surgical thresholds.
Indexed as
Identifiers
42920083What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.